SAG
OVID icon

SageView Advisory Group’s Ovid Therapeutics OVID Stock Holding History

SageView Advisory Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$72 Buy
+44
New +$68 ﹤0.01% 2556

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SageView Advisory Group's OVID Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Ovid Therapeutics (OVID) in Q4 2025: 44 shares worth $72. The stake represents ﹤0.01% of the portfolio and ranks #2556 among its holdings.

84 funds tracked by Wall St. Rank hold OVID as of Q4 2025.

  • SageView Advisory Group held 44 shares of Ovid Therapeutics worth $72 as of Q4 2025.
  • Ovid Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Ovid Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2556 holding.
  • 84 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.